Thomas Rogers, DO
Neurology · Cedar Rapids, IANPI 1588983589
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,458 of the $1,908 with a category attached, or 76.4%. It is spread thinly across 28 manufacturers, the largest accounting for just 24.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $754, 2.2 times the $343 reported in 2019.
Across 95 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$457
- Biogen$339
- AbbVie$212
- AstraZeneca$208
- Johnson & Johnson$78
- Amgen$67
- plus $545 from 22 others
What the payments were for
- Consulting fees$30016%
- Speaking & faculty fees$1508%
- Food & beverage$1,45876%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 42 | $457 |
| Biogen | 4 | $339 |
| AbbVie(2 entities) | 10 | $212 |
| AstraZeneca | 4 | $208 |
| Johnson & Johnson(2 entities) | 3 | $78 |
| Amgen | 3 | $67 |
| Genentech USA, Inc. | 3 | $55 |
| Argenx US, Inc. | 2 | $50 |
| Novartis | 2 | $33 |
| UCB, Inc. | 1 | $32 |
| Eisai Inc. | 1 | $32 |
| Lilly USA, LLC | 2 | $28 |
| Lundbeck LLC | 2 | $27 |
| Livanova USA, Inc. | 2 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Abbott | 1 | $21 |
| Biomarin Pharmaceutical Inc. | 1 | $19 |
| Catalyst Pharmaceuticals, Inc. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| EMD Serono, Inc. | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| MDD US Operations, LLC | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,908 in reported general payments places this provider in the 65th percentile of 132 neurology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 14 | $80,337 |
| NuplazidPimavanserin Tartrate | 15 | $72,980 |
| GlatopaGlatiramer Acetate | 24 | $54,417 |
| Dimethyl Fumarate | 70 | $50,461 |
| Emgality PenGalcanezumab-Gnlm | 62 | $48,141 |
| Glatiramer Acetate | 12 | $18,964 |
| FycompaPerampanel | 12 | $17,058 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 474 | $14,326 |
| Dalfampridine ErDalfampridine | 49 | $14,217 |
| Nurtec OdtRimegepant Sulfate | 12 | $12,400 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 12 | $8,364 |
| Entacapone | 32 | $7,501 |
| Levetiracetam | 203 | $5,159 |
| Gabapentin | 262 | $5,070 |
| Memantine Hcl | 71 | $4,375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Fycompa | $32 | $17,05812 claims |
| PfizerNurtec Odt, Dilantin | $457 | $14,81834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 132 neurology providers in Iowa.
Other neurology in Cedar Rapids
- Winthrop RiskCedar Rapids$136K
- Scott GeislerCedar Rapids$87K
- Robert StruthersCedar Rapids$2K
- Shereen ChangCedar Rapids$2K
- Laurence KrainCedar Rapids$2K
- Stephanie JacksonCedar Rapids$852
- Bruce HughesDes Moines$1.8M
- Michael JacobyDes Moines$243K
- Lynn RankinDes Moines$181K
- Wendy ZadehDes Moines$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.